US20040037838A1 - Malaria vaccine - Google Patents
Malaria vaccine Download PDFInfo
- Publication number
- US20040037838A1 US20040037838A1 US10/463,841 US46384103A US2004037838A1 US 20040037838 A1 US20040037838 A1 US 20040037838A1 US 46384103 A US46384103 A US 46384103A US 2004037838 A1 US2004037838 A1 US 2004037838A1
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- vaccine
- peptide
- pbcs
- oxidized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940124735 malaria vaccine Drugs 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 100
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 56
- 229920001184 polypeptide Polymers 0.000 claims abstract description 44
- 229960005486 vaccine Drugs 0.000 claims abstract description 25
- 101710117490 Circumsporozoite protein Proteins 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims abstract description 16
- 201000004792 malaria Diseases 0.000 claims abstract description 16
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 15
- 241000224016 Plasmodium Species 0.000 claims abstract description 5
- 241000223960 Plasmodium falciparum Species 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 241000223980 Plasmodium falciparum NF54 Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 2
- 150000001945 cysteines Chemical group 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 3
- 239000003094 microcapsule Substances 0.000 abstract description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 18
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- 210000003046 sporozoite Anatomy 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 241000224017 Plasmodium berghei Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000255925 Diptera Species 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 101800001415 Bri23 peptide Proteins 0.000 description 4
- 101800000655 C-terminal peptide Proteins 0.000 description 4
- 102400000107 C-terminal peptide Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000005996 Blood meal Substances 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 101100508406 Caenorhabditis elegans ifa-1 gene Proteins 0.000 description 1
- 101100508407 Caenorhabditis elegans mua-6 gene Proteins 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000017259 schizogony Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a vaccine against malaria.
- the invention further relates to polypeptides that are capable of eliciting an immunological and protective response against malaria in a subject and the use thereof in prophylaxis.
- Malaria is a parasitic disease transmitted during the blood meal of infected mosquitoes which inoculate sporozoites into the mammalian host. Within minutes, sporozoites invade hepatocytes and develop into merozoites intracellularly by asexual schizogony. The merozoites then invade red blood cells, producing the various symptoms associated with the disease. The life-cycle is completed when gametocytes are ingested during the blood meal of the mosquito vectors.
- the present invention provides vaccines against malaria, in particular for use in humans, comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptide at least comprises the four terminal cysteines from which at least one pair is oxidized, the vaccine optionally further comprising a suitable carrier and/or adjuvant and/or biodegradable microspheres.
- Biodegradable microcapsules are spheres of about 1 to 10 ⁇ m and very suitable carriers and/or adjuvants for the vaccine of the invention.
- the vaccine of the invention is based on the circumsporozoite protein of Plasmodium falciparum , more specifically of Plasmodium falciparum strain NF54.
- the polypeptide in the vaccine consists of at least 42 consecutive amino acids derived from the C-terminal part of the circumsporozoite protein. More in particular, the invention relates to vaccines in which the polypeptide comprises at least the amino acids 342 to 383 of Plasmodium falciparum , even more in particular the amino acids 342 to 383 of the Plasmodium falciparum NF-54 strain.
- all four cysteines present in the polypeptide derived from the C-terminal part of the circumsporozoite protein of Plasmodium falciparum are oxidized.
- the various Montanide ISA group of adjuvants are used as water-in-oil emulsions, oil-in-water emulsions, or water-in-oil-in-water emulsions.
- the different adjuvants accommodate different aqueous phase/oil phase ratios, because of the variety of surfactant and oil combinations.
- the performance of these adjuvants is said to be similar to Incomplete Freund's Adjuvant (IFA) for antibody production; however the inflammatory response is usually less.
- IFA Incomplete Freund's Adjuvant
- the invention further relates to polypeptides having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptides comprise at least 42 consecutive C-terminal amino acids of which one or more cysteine pairs are oxidized.
- polypeptide comprises the amino acids 342 to 383 of Plasmodium falciparum NF-54 strain.
- the invention relates to such polypeptide for use in a vaccine against malaria and to the use of such a polypeptide for the preparation of a vaccine against malaria.
- FIG. 1 Specificity of CTL bulk cultures obtained from spleen of mice immunized twice with 50 ⁇ g of peptide PbCS 242-310 in IFA. Specificity was determined 7 days after in vitro stimulation with the indicated peptide in a standard chromium release assay in the presence of target cells alone (open symbols) or pulsed with the corresponding peptide (filled symbols);
- FIG. 2 Specificity of CTL bulk cultures of spleen cells isolated from mice immunized twice with peptide PbCS 242-310 in IFA; specificity was assessed 7 days after in vitro stimulation with the indicated peptide in a standard chromium release assay with L cells transfected with Kd, Dd or Ld and pulsed with the specific peptide.
- FIG. 3 The determination of peptide PbCS 245-253 specific T cells by IFN- ⁇ ELISPOT in lymph node (LN) cells. Mice were immunized with various antigen preparations in IFA at the base of the tail on day 0 and 3-4 weeks later. Panel A shows peptide PbCS 242-310 or peptides P30/PbCS 245-253; panel B shows reduced or oxidized PbCS 242-310. Inguinal and periaortic draining lymph nodes of two mice per group were removed 10-20 days after the second injection and cells obtained were pooled.
- T cells The presence of specific T cells was assessed directly by ELISPOT in the presence of irradiated P815 cells pulsed or not with peptide PbCS 245-253. Mice immunized with IFA only were used as controls. Results are representative of three experiments performed and are expressed as the difference of spots obtained when cells were incubated with or without the PbCS peptide 245-252;
- FIG. 4 Pf CS 282-383 specific antibodies evaluated one month after the first immunization. As in FIG. 2, the presence of Pf CS 282-383 specific antibodies was evaluated by ELISA in volunteers immunized in the presence of MontanideTM ISA-720 (upper panel) or Alum (lower panel), at two peptide doses (100 or 300 ⁇ g, filled or empty symbols, respectively).
- FIG. 5 Evolution of lymphocyte proliferation to Pf CS 282-383 in volunteers immunized with 100 ⁇ g of peptide in the presence of MontanideTM ISA-720.
- Peripheral Blood Lymphocytes (PBL) from 4 volunteers (Nos. 1, 4, 6 and 11) before (month 0) and after (months 1-8) immunizations were tested in a 6 day culture with Pf CS 282-383 at various concentrations (30-0.04 ⁇ g/ml). Data are shown as the highest average stimulation index (S.I.) of 5 replicate cultures. Control cultures (TT and PHA) gave satisfactory S.I. Arrows indicate time of injections. * not tested.
- S.I. stimulation index
- the 9-mer peptide PbCS 245-253 corresponds to an identified CTL epitope (Romero et al, Nature 341:323-326 (1989)).
- Polypeptide PbCS 242-310 covering the C-terminal region of the circumsporozoite protein of Plasmodium berghei ANKA strain was obtained as previously described in detail for the Plasmodium falciparum analogue (Roggero et al., Mol. lmmunol. 32:1301-1309 (1995)).
- the polypeptide was prepared on a p-alkoxybenzylalcohol resin (Wang resin) with a degree of substitution of 0.4 mmol/g. A 10-fold excess of F-moc amino acid derivatives and a 30 min coupling time were used.
- the crude polypeptide was purified by a combination of size exclusion chromatography (Sephadex 025, Pharmacia, Sweden) and RP-HPLC (W-Porex 5 C4, 250 ⁇ 10 mm, Phenomenex, Collinso Palos Verdes, USA using a 10-50% CH 3 CN gradient in 0.1% TFA/H 2 O in 40 min with a flow rate of 3 ml/min).
- the reduced form of PbCS 242-310 was obtained by treating the HPLC purified polypeptide with a 100 molar excess of DTT for 36 h at 37EC. After elimination of the DTT excess by size exclusion chromatography, a portion of the material was dissolved in 0.1 M CH 3 COONH 4 pH 8.0 and left to air oxidize for 10 days. The complete reduction or oxidation of the peptide was confirmed both by the Ellman reaction and by adding a 1000 molar excess of N-ethylmaleimide (NEM) to an aliquot of the peptide solution. In the later case, after incubation at 4° C. for 1 h, no increase of the polypeptide MW was detected by mass spectrometry for the oxidized form while the reduced form presented a MW increase corresponding to the addition of four NEM molecules.
- NEM N-ethylmaleimide
- mice Four- to five-weeks old female BALB/c mice were purchased from Harlan (Zeist, NL). Mice were injected subcutaneously at the base of the tail with 50 ⁇ g reduced or oxidized polypeptide dissolved in PBS and emulsified in incomplete Freund's adjuvant (IFA). For the short peptide PbCS 245-253, 4 ⁇ g were injected in combination with 100 ⁇ g of the universal helper peptide P30 (Renggli et al., Immunol. Let. 46:199-205 (1995)). Animals received a booster dose of immunogen after 2-3 weeks. Seven to ten days after the peptide boost, mice were bled to assess the production of specific antibodies. Subsequently, the animals were either sacrificed for proliferation, CTL or ELISPOT assays or exposed to sporozoite-bearing mosquitoes.
- IFA incomplete Freund's adjuvant
- Plasmodium berghei (ANKA strain; clone 1, Dr. Walliker, Edinburgh or clone Dr. P. H. Lambert, WHO, Geneva) sporozoites were produced by cyclical transmission to laboratory-bred Anopheles gambiae or A.stephensi mosquitoes. Mice were anaesthetized and exposed to infected mosquitoes. Mice were individually exposed to a previously determined number of bites necessary to obtain a complete infection in naive age-matched BALB/c mice. After parasite challenge, parasitemia was checked regularly from day 5 to day 14 by Giemsa-stained blood smears. Mice were considered protected when no parasites were detected 14 days after the challenge.
- Hybridomas H35 CD8-specific rat IgG2b
- GK1.5 CD4-specific rat IgG2b
- Challenge was performed at day 0.
- One mg of CD4-specific antibodies was injected at days ⁇ 3, ⁇ 2 and ⁇ 1 (same protocol for control Rat Ig's).
- Half mg of CD8-specific antibodies was injected at days ⁇ 2 and +2.
- Nitrocellulose ELISPOT plates were coated overnight in a humid chamber at 4° C. with a PBS solution containing 100 ⁇ g/ml of IFN- ⁇ -specific antibody OIE703B2 (Slade and Langhorne, Immunobiology 179, 353, (1989)). A saturation step was performed by adding DMEM containing 10% FCS for 2 hours at 37° C. Immune cells isolated from the draining lymph nodes of immunized mice were then co-cultured in the plates with 100,000 irradiated P815 cells/well pulsed or not with the short peptide PbCS 245-253, 24 hours at 37° C.
- IFN- ⁇ specific biotinylated antibody (ANI) (Slade and Langhorne, Immunobiology 179, 353 (1989)) was added (1 ⁇ g/ml in PBS-1 BSA) for 2 hours at 37° C. After washing, streptavidin-alkaline phosphatase conjugate diluted in PBS-5% FCS was added for 1 hour at 37° C. and the presence of immune complexes revealed by the addition of BCIP/NBT substrate.
- mice were immunized twice with peptide PbCS 242-310 in IFA.
- the presence of peptide-specific antibodies was assessed 7-10 days after the second injection.
- a high titer of peptide-specific antibodies (1:300,000) was detected by ELISA and cross-reactivity with the native CS protein (1:25,000) was demonstrated by IFAT assays on P.berghei air-dried sporozoites. Recognition was specific since it was inhibited by the addition of competitor PbCS 242-310 peptide.
- the cytotoxic activity was equivalent to that obtained in mice immunized with the optimal nonameric peptide PbCS 245 - 253 as determined by the numbers of IFN- ⁇ spot forming cells (FIG. 1A).
- the Kd restriction of the CTL response was confirmed using transfected L cells expressing Kd, Dd or Ld MHC class I molecules (FIG. 2).
- mice immunized twice subcutaneously at the base of the tail with 50 ⁇ g PbCS 242-310 peptide in IFA were submitted to a parasite challenge 7-10 days after the peptide boost.
- An important level of specific protection was obtained in PbCS 242-310 peptide-immunized mice (Table 2, Experiment A).
- the fully reduced C-terminal peptide was allowed to undergo full oxidation by air-exposing it in an aqueous solution at pH 8.0 for 10 days at room temperature.
- the immunological properties of this preparation were then compared with the fully reduced material in terms of CTL response and protective capacity. While there is no qualitative difference in antibody titers and T-cell proliferation, the number of IFN- ⁇ ELISPOT obtained with the oxidized material in three different experiments was consistently greater than that observed for the fully reduced peptide (FIG. 3B). Similarly, the degree of protection obtained with the oxidized material was consistently higher than that observed with the reduced molecule (Table 2, Experiments B, C).
- T helper cells and antibodies can independently provide protection against malaria exoerythrocytic stages.
- This experiment shows that the peptide-specific antibodies also have the capability to recognize the native protein on P.berghei sporozoites and, therefore, it is assumed that they can neutralize sporozoites in vivo. This leads to a reduction in the number of infected hepatocytes and to protection, mediated by CD8 + T cells as a result of the modification of the balance between the hepatic stages and CD8 + T cells in favor of these latter.
- CD4 + T cells may play a crucial role in the initiation of a peptide-specific immune response by providing help to specific CTL or B cells.
- the synthetic peptide Pf CS 282-383 corresponding to the C-terminal end of the circumsporozoite protein of the Plasmodium falciparum NF-54 strain has being evaluated as a potential malaria vaccine; this study was initiated following pre-clinical studies that indicated its capacity to elicit antibodies, lymphocyte proliferation and cytotoxic T lymphocytes (CTL), as well as to protect from malaria infection in various animal models.
- CTL cytotoxic T lymphocytes
- the peptide was synthesized, purified and bottled sterilely in glass vials appropriate for every test dose.
- the quality of the preparation fulfills the criteria of a GLP product for human use.
- Table 3 suumarizes the results of an experiment in which the specific CD8 response was evaluated for HLA-A* 0201 epitopes of Pf CS NF54 (334-342) before immunization, 2 or 3 months after the second and 3 months after the third immunization.
- IFN- ⁇ producing cells were enumerated by ELISPOT using different methods of spot counting in parallel, visual and 2 different ELISPOT readers (AID 1.2 and BioSys). Depending on the method of counting, different results were obtained.
- CD8 specific response in HLA-A* 0201 volunteers before and after the second and third immunizations before*** immuni- after the second after the third Pf CS 334-342 zation immunization immunization CD8 mean 134 ⁇ 165 845 ⁇ 974 2046 ⁇ 2433 frequency* response ⁇ sd range of — [1017; 1542] [967; 7567] positive responses Responders** good 0/8 2/8 5/8 responders inter- 4/8 5/8 2/8 mediate responders non- 4/8 1/8 1/8 responders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a vaccine against malaria comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, in which polypeptide one or more pairs of cysteine residues are oxidized, and optionally a suitable carrier and/or adjuvant and/or biodegradable microcapsules for use in humans.
Description
- The present invention relates to a vaccine against malaria. The invention further relates to polypeptides that are capable of eliciting an immunological and protective response against malaria in a subject and the use thereof in prophylaxis.
- Malaria is a parasitic disease transmitted during the blood meal of infected mosquitoes which inoculate sporozoites into the mammalian host. Within minutes, sporozoites invade hepatocytes and develop into merozoites intracellularly by asexual schizogony. The merozoites then invade red blood cells, producing the various symptoms associated with the disease. The life-cycle is completed when gametocytes are ingested during the blood meal of the mosquito vectors.
- Protective immunity against malaria can be obtained by immunizing mice and humans with irradiation-attenuated sporozoites. This immunity is the result of the effect of neutralizing antibodies recognizing free sporozoites in the blood stream and of CD4+ and CD8+ T cells which prevent the development of the parasite hepatic forms. Experiments performed in B cell deficient mice have demonstrated that, despite the absence of anti-sporozoite antibodies, protection is induced by irradiated sporozoite immunization. This suggests that T cells specific for proteins present in the intracellular hepatic stage play a predominant role in protection. Therefore, one of the aims in malaria vaccine research is to mimic the protective immune response induced by injection of irradiated sporozoites.
- In the research that led to the present invention it was found that a polypeptide of 69 amino acids (PbCS 242-310) encompassing the C-terminal region35 of the circumsporozoite protein of Plasmodium berghei, which was generated using solid-phase peptide synthesis elicited in BALB/c mice (H-2d) after two subcutaneous injections, in the presence of Incomplete Freund's Adjuvant (IFA) at the base of the tail, (i) high titers of anti-peptide antibodies which also recognize the native P.berghei CS protein, (ii) cytolytic T cells specific for the Major Histocompatibility Complex (MHC) antigen Kd restricted peptide PbCS 245-253, and (iii) partial CD8+-dependent protection against sporozoite-induced malaria. The same frequencies of peptide PbCS 245-253 specific cytotoxic T lymphocytes (CTL) were found by IFN-γ ELISPOT in the draining lymph nodes of animals immunized with the short optimal CTL peptide 245-253 or with the polypeptide 242-310, indicating that the longer polypeptide can be processed and presented in vivo in the context of MHC class I as efficiently as short CTL peptides. Interestingly, even higher levels of CTL activity and protection were observed when the four cysteine residues present in the C-terminal peptide were fully oxidized. These findings underline the potential importance of the chemical nature of the C-terminal fragment on the activation of the immune system and concomitant protection. And more generally, as multiple facets of the immune system are stimulated by long synthetic polypeptides, these may provide a valuable alternative to vaccination with recombinant protein fragments or short peptides.
- Based on this finding the present invention provides vaccines against malaria, in particular for use in humans, comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptide at least comprises the four terminal cysteines from which at least one pair is oxidized, the vaccine optionally further comprising a suitable carrier and/or adjuvant and/or biodegradable microspheres. Biodegradable microcapsules are spheres of about 1 to 10 μm and very suitable carriers and/or adjuvants for the vaccine of the invention.
- Specifically, the vaccine of the invention is based on the circumsporozoite protein ofPlasmodium falciparum, more specifically of Plasmodium falciparum strain NF54.
- Preferably the polypeptide in the vaccine consists of at least 42 consecutive amino acids derived from the C-terminal part of the circumsporozoite protein. More in particular, the invention relates to vaccines in which the polypeptide comprises at least the amino acids 342 to 383 ofPlasmodium falciparum, even more in particular the amino acids 342 to 383 of the Plasmodium falciparum NF-54 strain.
- Preferably, all four cysteines present in the polypeptide derived from the C-terminal part of the circumsporozoite protein ofPlasmodium falciparum are oxidized.
- It was found that the vaccine of the invention is in particular useful when the adjuvant is Montanidem™. Montanide™ ISA Adjuvants (Seppic, Paris, France; ISA=Incomplete Seppic Adjuvant) are a group of oil/surfactant based adjuvants in which different surfactants are combined with either a non-metabolizable mineral oil, a metabolizable oil, or a mixture of the two. They are prepared for use as an emulsion with aqueous Antigen solution. The various Montanide ISA group of adjuvants are used as water-in-oil emulsions, oil-in-water emulsions, or water-in-oil-in-water emulsions. The different adjuvants accommodate different aqueous phase/oil phase ratios, because of the variety of surfactant and oil combinations. The performance of these adjuvants is said to be similar to Incomplete Freund's Adjuvant (IFA) for antibody production; however the inflammatory response is usually less.
- The invention further relates to polypeptides having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptides comprise at least 42 consecutive C-terminal amino acids of which one or more cysteine pairs are oxidized.
- In a particular embodiment of the invention the polypeptide comprises the amino acids342 to 383 of Plasmodium falciparum NF-54 strain.
- It is preferred that all cysteine residues present in the polypeptide are oxidized.
- Furthermore, the invention relates to such polypeptide for use in a vaccine against malaria and to the use of such a polypeptide for the preparation of a vaccine against malaria.
- The present invention will be further elucidated in the examples that follow, and which are in no way intended to be limiting to the invention.
- In the examples reference is made to the accompanying figures which show:
- FIG. 1: Specificity of CTL bulk cultures obtained from spleen of mice immunized twice with 50 μg of peptide PbCS 242-310 in IFA. Specificity was determined 7 days after in vitro stimulation with the indicated peptide in a standard chromium release assay in the presence of target cells alone (open symbols) or pulsed with the corresponding peptide (filled symbols);
- FIG. 2: Specificity of CTL bulk cultures of spleen cells isolated from mice immunized twice with peptide PbCS 242-310 in IFA; specificity was assessed 7 days after in vitro stimulation with the indicated peptide in a standard chromium release assay with L cells transfected with Kd, Dd or Ld and pulsed with the specific peptide.
- FIG. 3: The determination of peptide PbCS 245-253 specific T cells by IFN-γ ELISPOT in lymph node (LN) cells. Mice were immunized with various antigen preparations in IFA at the base of the tail on
day 0 and 3-4 weeks later. Panel A shows peptide PbCS 242-310 or peptides P30/PbCS 245-253; panel B shows reduced or oxidized PbCS 242-310. Inguinal and periaortic draining lymph nodes of two mice per group were removed 10-20 days after the second injection and cells obtained were pooled. The presence of specific T cells was assessed directly by ELISPOT in the presence of irradiated P815 cells pulsed or not with peptide PbCS 245-253. Mice immunized with IFA only were used as controls. Results are representative of three experiments performed and are expressed as the difference of spots obtained when cells were incubated with or without the PbCS peptide 245-252; - FIG. 4: Pf CS 282-383 specific antibodies evaluated one month after the first immunization. As in FIG. 2, the presence of Pf CS 282-383 specific antibodies was evaluated by ELISA in volunteers immunized in the presence of Montanide™ ISA-720 (upper panel) or Alum (lower panel), at two peptide doses (100 or 300 μg, filled or empty symbols, respectively).
- FIG. 5: Evolution of lymphocyte proliferation to Pf CS 282-383 in volunteers immunized with 100 μg of peptide in the presence of Montanide™ ISA-720. Peripheral Blood Lymphocytes (PBL) from 4 volunteers (Nos. 1, 4, 6 and 11) before (month 0) and after (months 1-8) immunizations were tested in a 6 day culture with Pf CS 282-383 at various concentrations (30-0.04 μg/ml). Data are shown as the highest average stimulation index (S.I.) of 5 replicate cultures. Control cultures (TT and PHA) gave satisfactory S.I. Arrows indicate time of injections. * not tested.
- Elevation of the immune response against a circumsporozoite derived polypeptide in a murine model
- Materials and Methods
- 1. Peptide Synthesis and Analysis
- All the peptides used in this example were chemically synthesized using solid phase F-moc chemistry, as described by Atherton et al. (Peptides synthesis,
Part 2. Bioorg. Chem. 8:350-351 (1979)). Chemicals and solvents used for the synthesis were purchased from Bachem Feinchemikallien (Buddendorf, Switzerland), Novabiochem (Laufelfingen, Switzerland) and Fluka (Buchs, Switzerland). - The 9-mer peptide PbCS 245-253 corresponds to an identified CTL epitope (Romero et al, Nature 341:323-326 (1989)). Polypeptide PbCS 242-310 covering the C-terminal region of the circumsporozoite protein of Plasmodium berghei ANKA strain (Lanar,Mol. Bioch. Paras. 39:151-153 (1990)) was obtained as previously described in detail for the Plasmodium falciparum analogue (Roggero et al., Mol. lmmunol. 32:1301-1309 (1995)). Briefly, the polypeptide was prepared on a p-alkoxybenzylalcohol resin (Wang resin) with a degree of substitution of 0.4 mmol/g. A 10-fold excess of F-moc amino acid derivatives and a 30 min coupling time were used. The crude polypeptide was purified by a combination of size exclusion chromatography (Sephadex 025, Pharmacia, Sweden) and RP-HPLC (W-
Porex 5 C4, 250×10 mm, Phenomenex, Rancho Palos Verdes, USA using a 10-50% CH3CN gradient in 0.1% TFA/H2O in 40 min with a flow rate of 3 ml/min). - The 20-mer peptides B11-B17 (Table 1) which overlap by 10 residues and encompass the sequence PbCS 233-312 were purified by size exclusion chromatography. The degree of purity of all peptides was analyzed by RP-HPLC (C18 analytical column). Amino acid composition of purified peptides was determined according to Knecht and Chang (Anal. Chem. 58:2375-2379 (1986)) and the molecular weight was confirmed by mass spectrometry on an LDI 1700 Mass Monitor (Linear Scientific Inc., Reno, Nev., USA) or a Voyager-DE (PerSeptive Byosystem, Framingham, Mass., USA).
- 2. Reduction and Oxidization of PbCS 242-310
- The reduced form of PbCS 242-310 was obtained by treating the HPLC purified polypeptide with a 100 molar excess of DTT for 36 h at 37EC. After elimination of the DTT excess by size exclusion chromatography, a portion of the material was dissolved in 0.1 M CH3COONH4 pH 8.0 and left to air oxidize for 10 days. The complete reduction or oxidation of the peptide was confirmed both by the Ellman reaction and by adding a 1000 molar excess of N-ethylmaleimide (NEM) to an aliquot of the peptide solution. In the later case, after incubation at 4° C. for 1 h, no increase of the polypeptide MW was detected by mass spectrometry for the oxidized form while the reduced form presented a MW increase corresponding to the addition of four NEM molecules.
- 3. Immunization
- Four- to five-weeks old female BALB/c mice were purchased from Harlan (Zeist, NL). Mice were injected subcutaneously at the base of the tail with 50 μg reduced or oxidized polypeptide dissolved in PBS and emulsified in incomplete Freund's adjuvant (IFA). For the short peptide PbCS 245-253, 4 μg were injected in combination with 100 μg of the universal helper peptide P30 (Renggli et al.,Immunol. Let. 46:199-205 (1995)). Animals received a booster dose of immunogen after 2-3 weeks. Seven to ten days after the peptide boost, mice were bled to assess the production of specific antibodies. Subsequently, the animals were either sacrificed for proliferation, CTL or ELISPOT assays or exposed to sporozoite-bearing mosquitoes.
- 4. Parasite Challenge
-
clone 1, Dr. Walliker, Edinburgh or clone Dr. P. H. Lambert, WHO, Geneva) sporozoites were produced by cyclical transmission to laboratory-bred Anopheles gambiae or A.stephensi mosquitoes. Mice were anaesthetized and exposed to infected mosquitoes. Mice were individually exposed to a previously determined number of bites necessary to obtain a complete infection in naive age-matched BALB/c mice. After parasite challenge, parasitemia was checked regularly fromday 5 to day 14 by Giemsa-stained blood smears. Mice were considered protected when no parasites were detected 14 days after the challenge. - 5. T Cell Depletion in Vivo
- Hybridomas H35 (CD8-specific rat IgG2b) (Golstein et al.,Immunol. Rev. 68:5-42 (1982)) and GK1.5 (CD4-specific rat IgG2b) (Dialynas et al., J. lmmunol. 131:2445-2451 (1983)) were used as a source for antibodies. Challenge was performed at
day 0. One mg of CD4-specific antibodies was injected at days −3, −2 and −1 (same protocol for control Rat Ig's). Half mg of CD8-specific antibodies was injected at days −2 and +2. - Depletion was >95% during the time required for the complete development ofP. berghei liver stages (Meis et al., Am. J. Trop. Med. Hyq. 37:506-10 (1987)). Depletion was verified by FACS (Becton Dickinson) analysis of peripheral blood lymphocytes (PBL) or spleen cells using CD4-specific FITC labelled (Ref. 1300 024, Boehringer Mannheim, Germany) and CD8-specific PE labelled (Ref. 1271 237, Boehringer Mannheim, Germany).
- 6. ELISPOT Assay
- Nitrocellulose ELISPOT plates were coated overnight in a humid chamber at 4° C. with a PBS solution containing 100 μg/ml of IFN-γ-specific antibody OIE703B2 (Slade and Langhorne,Immunobiology 179, 353, (1989)). A saturation step was performed by adding DMEM containing 10% FCS for 2 hours at 37° C. Immune cells isolated from the draining lymph nodes of immunized mice were then co-cultured in the plates with 100,000 irradiated P815 cells/well pulsed or not with the short peptide PbCS 245-253, 24 hours at 37° C. Cells were then removed and a second IFN-γ specific biotinylated antibody (ANI) (Slade and Langhorne, Immunobiology 179, 353 (1989)) was added (1 μg/ml in PBS-1 BSA) for 2 hours at 37° C. After washing, streptavidin-alkaline phosphatase conjugate diluted in PBS-5% FCS was added for 1 hour at 37° C. and the presence of immune complexes revealed by the addition of BCIP/NBT substrate.
- Results
-
- BALB/c mice were immunized twice with peptide PbCS 242-310 in IFA. The presence of peptide-specific antibodies was assessed 7-10 days after the second injection. A high titer of peptide-specific antibodies (1:300,000) was detected by ELISA and cross-reactivity with the native CS protein (1:25,000) was demonstrated by IFAT assays onP.berghei air-dried sporozoites. Recognition was specific since it was inhibited by the addition of competitor PbCS 242-310 peptide.
- To assess the CTL response, spleen and LN immune cells were restimulated in vitro with the well known CTL epitope PbCS 245-253, peptide PbCS 242-310 and overlapping peptides B11-B17 covering the entire C-terminal sequence. High levels of cytotoxicity were detected in spleens and lymph nodes of immunized mice restimulated with peptides 245-253 and 243-262, whereas lower levels were induced by peptides 233-252 and 242-310 (FIG. 1, Table 1).
TABLE 1 Peptides used in the study Code Sequence B11 233-252 B12 243-262 B13 253-272 B14 263-282 B15 273-292 B16 283-302 B17 293-312 PbCS 245-253 245-253 PbCS 242-310 242-310 - The cytotoxic activity was equivalent to that obtained in mice immunized with the optimal nonameric peptide PbCS245-253 as determined by the numbers of IFN-γ spot forming cells (FIG. 1A). The Kd restriction of the CTL response was confirmed using transfected L cells expressing Kd, Dd or Ld MHC class I molecules (FIG. 2).
- 2. Immunization with PbCS 242-310 Peptide in IFA Confers CD8+-Dependent Protection to BALB/c Mice Exposed to Parasite-Bearinq Mosquitoes
- BALB/c mice immunized twice subcutaneously at the base of the tail with 50 μg PbCS 242-310 peptide in IFA were submitted to a parasite challenge 7-10 days after the peptide boost. An important level of specific protection was obtained in PbCS 242-310 peptide-immunized mice (Table 2, Experiment A).
TABLE 2 Ex- Protected/ % periment Immunization Treatment Exposed Protection A IFA anti-CD4 2/9 22 reduced PbCS 242-310 anti-CD8 12/20 60 reduced PbCS 242-310 3/20 15 reduced PbCS 242-310 12/20 60 B IFA 1/7 14 oxidized PbCS 242-310 6/7 84 C IFA 2/8 25 reduced PbCS 242-310 4/8 50 oxidized PbCS 242-310 8/8 100 - In order to characterize the mechanisms of protection, T cell depletion was performed in vivo. Clearly, the depletion of CD4+ T cells did not significantly modify the observed protection. In contrast, depletion of CD8+ T cells by isotype matched CD8-specific antibodies prevented peptide-induced protection in vivo, since a baseline level of protection was observed (Table, Experiment A).
- 3. Immunological Properties of the Oxidized PbCS 242-310 C-Terminal Peptide
- The fully reduced C-terminal peptide was allowed to undergo full oxidation by air-exposing it in an aqueous solution at pH 8.0 for 10 days at room temperature. The immunological properties of this preparation were then compared with the fully reduced material in terms of CTL response and protective capacity. While there is no qualitative difference in antibody titers and T-cell proliferation, the number of IFN-γ ELISPOT obtained with the oxidized material in three different experiments was consistently greater than that observed for the fully reduced peptide (FIG. 3B). Similarly, the degree of protection obtained with the oxidized material was consistently higher than that observed with the reduced molecule (Table 2, Experiments B, C).
- In this example injection of a long synthetic polypeptide covering the C-terminal region of the CS protein conferred CD8+-dependent protection against Plasmodium berghei. Interestingly, the CTL response against peptide PbCS 245-253 is elicited in both cases to a similar extent in immunized mice. In fact, the CTL frequencies determined by ELISPOT are similar in mice immunized either with the short PbCS 245-253 CTL peptide or the long PbCS 242-310 peptide. Since it is known that no protection is observed upon injection of the CTL epitope, the present experiments indicate that parasite specific T helper cells and antibodies specific for peptide PbCS 242-310 and the native CS protein also play a role in anti-parasite immunity.
- It is known that T helper cells and antibodies can independently provide protection against malaria exoerythrocytic stages. This experiment shows that the peptide-specific antibodies also have the capability to recognize the native protein onP.berghei sporozoites and, therefore, it is assumed that they can neutralize sporozoites in vivo. This leads to a reduction in the number of infected hepatocytes and to protection, mediated by CD8+ T cells as a result of the modification of the balance between the hepatic stages and CD8+ T cells in favor of these latter.
- In addition to generating antibodies, injection of peptide PbCS 242-310 also induced Th1 cell proliferation (data not shown), although protection does not seem to be dependent on CD4+ T cells. Here, CD4+ T cells may play a crucial role in the initiation of a peptide-specific immune response by providing help to specific CTL or B cells.
- The present results demonstrate that long polypeptides are efficient immunogens when injected in IFA. Here, immunization with peptide PbCS 242-310 not only generates a wide spectrum of immune responses but also provides CD8+-dependent protection against sporozoite-induced infection. In particular and unexpectedly, the oxidized material induces a higher number of CTL precursors and leads to a better degree of protection against a sporozoite challenge.
- The data of this experiment were the foundation for using the oxidized CS terminal fragment ofP.falciparum in an on-going Phase I human trial. The result obtained show that similar antibody, T cell proliferation and CTL responses are also obtained in humans (cf. Example 2).
- Immune Response in Humans Against the C-Terminal, Oxidized Fragment of the Circumsporozoite Protein ofPlasmodium falciparum
- 1. Introduction
- The synthetic peptide Pf CS 282-383 corresponding to the C-terminal end of the circumsporozoite protein of thePlasmodium falciparum NF-54 strain has being evaluated as a potential malaria vaccine; this study was initiated following pre-clinical studies that indicated its capacity to elicit antibodies, lymphocyte proliferation and cytotoxic T lymphocytes (CTL), as well as to protect from malaria infection in various animal models. The evaluation has been designed as an open, non-randomized, phase I clinical trial aimed at establishing the safety of the peptide, when injected in the presence of adjuvants.
- 2. Peptide Characteristics
- The peptide was synthesized, purified and bottled sterilely in glass vials appropriate for every test dose. The quality of the preparation fulfills the criteria of a GLP product for human use.
- 3. Results
- As seen in FIGS. 4 and 5 antibody response and T-cell proliferation are obtained after immunization of naive volunteers with 100 μg of antigen in Montanide™ ISA-720, Similarly, a CD8 dependent IFN-γ production is observed after immunization (Table 3).
- Table 3 suumarizes the results of an experiment in which the specific CD8 response was evaluated for HLA-A* 0201 epitopes of Pf CS NF54 (334-342) before immunization, 2 or 3 months after the second and 3 months after the third immunization. Specifically IFN-γ producing cells were enumerated by ELISPOT using different methods of spot counting in parallel, visual and 2 different ELISPOT readers (AID 1.2 and BioSys). Depending on the method of counting, different results were obtained.
TABLE 3 CD8 specific response in HLA-A* 0201 volunteers before and after the second and third immunizations before*** immuni- after the second after the third Pf CS 334-342 zation immunization immunization CD8 mean 134 ± 165 845 ± 974 2046 ± 2433 frequency* response ± sd range of — [1017; 1542] [967; 7567] positive responses Responders** good 0/8 2/8 5/8 responders inter- 4/8 5/8 2/8 mediate responders non- 4/8 1/8 1/8 responders - In conclusion, the present examples provide evidence that long synthetic polypeptides represent a valuable alternative for the production of vaccines capable of stimulating multiple facets of the immune system.
Claims (17)
1. A vaccine against malaria, in particular for use in humans, comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptide at least comprises the four terminal cysteines from which at least one pair is oxidized, the vaccine optionally further comprising a suitable carrier and/or adjuvant and/or biodegradable microspheres.
2. A vaccine as claimed in claim 1 wherein the circumsporozoite protein is of Plasmodium falciparum.
3. A vaccine as claimed in claim 2 , wherein the circumsporozoite protein is of Plasmodium falciparum strain NF54.
4. A vaccine as claimed in claims 1-3, wherein the polypeptide consists of at least 42 consecutive amino acids derived from the C-terminal part of the circumsporozoite protein.
5. A vaccine as in claims 1-4, wherein the polypeptide comprises the C-terminal amino acids 342 to 383 of Plasmodium falciparum NF54.
6. A vaccine as in claims 1-5, wherein all cysteines are oxidized.
7. A vaccine as in claims 1-6, wherein the adjuvant is Montanide™.
8. A vaccine as claimed in claim 1-7 for use in the prophylaxis of malaria.
9. Use of a vaccine as claimed in claims 1-7 in the prophylaxis of malaria.
10. Polypeptide for use in a vaccine against malaria, which polypeptide has the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, which polypeptide comprises the four terminal cysteines from which at least one pair is oxidized.
11. A polypeptide as claimed in claim 10 wherein the circumsporozoite protein is of Plasmodium falciparum.
12. A polypeptide as claimed in claim 11 , wherein the circumsporozoite protein is of Plasmodium falciparum strain NF54.
13. A polypeptide as claimed in claims 10-12, which polypeptide consists of at least 42 consecutive amino acids derived from the C-terminal part of the circumsporozoite protein.
14. A polypeptide as in claims 10-13, which polypeptide comprises the C-terminal amino acids 342 to 383 of Plasmodium falciparum NF54.
15. A polypeptide as in claims 10-14, wherein all cysteines are oxidized.
16. Polypeptide as claimed in claims 10-15 for use in a vaccine against malaria.
17. Use of one or more polypeptides as claimed in claims 10-15 for the preparation of a vaccine against malaria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/463,841 US20040037838A1 (en) | 1999-02-18 | 2003-06-16 | Malaria vaccine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99200476 | 1999-02-18 | ||
EP992004762 | 1999-02-18 | ||
US09/506,691 US6579524B1 (en) | 1999-02-18 | 2000-02-18 | Malaria vaccine |
US10/463,841 US20040037838A1 (en) | 1999-02-18 | 2003-06-16 | Malaria vaccine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,691 Division US6579524B1 (en) | 1999-02-18 | 2000-02-18 | Malaria vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040037838A1 true US20040037838A1 (en) | 2004-02-26 |
Family
ID=8239901
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,691 Expired - Fee Related US6579524B1 (en) | 1999-02-18 | 2000-02-18 | Malaria vaccine |
US10/463,841 Abandoned US20040037838A1 (en) | 1999-02-18 | 2003-06-16 | Malaria vaccine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,691 Expired - Fee Related US6579524B1 (en) | 1999-02-18 | 2000-02-18 | Malaria vaccine |
Country Status (15)
Country | Link |
---|---|
US (2) | US6579524B1 (en) |
EP (1) | EP1151098A1 (en) |
JP (1) | JP2002537310A (en) |
CN (1) | CN1341150A (en) |
AU (1) | AU765801B2 (en) |
BR (1) | BR0008285A (en) |
CA (1) | CA2359610A1 (en) |
CZ (1) | CZ292475B6 (en) |
HU (1) | HUP0200302A2 (en) |
IL (1) | IL144750A0 (en) |
MX (1) | MXPA01008176A (en) |
NZ (1) | NZ513549A (en) |
PL (1) | PL349861A1 (en) |
WO (1) | WO2000049146A1 (en) |
ZA (1) | ZA200105652B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200302A2 (en) * | 1999-02-18 | 2002-05-29 | Rmf Dictagene Sa | Malaria vaccine |
WO2004045559A2 (en) * | 2002-11-20 | 2004-06-03 | Sanaria Inc. | Method for the prevention of malaria |
FR2873386B1 (en) * | 2004-07-22 | 2011-01-14 | Agence Francaise De Securite Sanitaire Des Aliments Afssa | VACCINE COMPOSITION AGAINST RHODOCOCCUS EQUI |
US8063193B2 (en) * | 2009-03-27 | 2011-11-22 | Abbott Laboratories | Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof |
CA2769996C (en) * | 2009-11-05 | 2018-06-12 | The United States Of America As Represented By The Secretary Of The Na | Plasmodium falciparum sporozoite and liver stage antigens |
CN102906108B (en) | 2010-03-04 | 2016-01-20 | 菲尼克斯公司 | For preparing the method for solubility recombinant interferon albumen without sex change |
US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6169171B1 (en) * | 1992-02-27 | 2001-01-02 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBSAG |
US6579524B1 (en) * | 1999-02-18 | 2003-06-17 | Rmf Dictagene S.A. | Malaria vaccine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU625713B2 (en) * | 1988-02-19 | 1992-07-16 | Microgenesys, Inc. | Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum |
US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
AU1762092A (en) * | 1991-04-01 | 1992-11-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria |
WO1994006464A1 (en) * | 1992-09-17 | 1994-03-31 | New York University | Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites |
-
2000
- 2000-02-17 HU HU0200302A patent/HUP0200302A2/en unknown
- 2000-02-17 JP JP2000599871A patent/JP2002537310A/en active Pending
- 2000-02-17 NZ NZ513549A patent/NZ513549A/en unknown
- 2000-02-17 CN CN00803951A patent/CN1341150A/en active Pending
- 2000-02-17 CA CA002359610A patent/CA2359610A1/en not_active Abandoned
- 2000-02-17 CZ CZ20012957A patent/CZ292475B6/en not_active IP Right Cessation
- 2000-02-17 BR BR0008285-6A patent/BR0008285A/en not_active IP Right Cessation
- 2000-02-17 WO PCT/EP2000/001335 patent/WO2000049146A1/en not_active Application Discontinuation
- 2000-02-17 AU AU28057/00A patent/AU765801B2/en not_active Ceased
- 2000-02-17 IL IL14475000A patent/IL144750A0/en unknown
- 2000-02-17 MX MXPA01008176A patent/MXPA01008176A/en unknown
- 2000-02-17 EP EP00906347A patent/EP1151098A1/en not_active Withdrawn
- 2000-02-17 PL PL00349861A patent/PL349861A1/en not_active Application Discontinuation
- 2000-02-18 US US09/506,691 patent/US6579524B1/en not_active Expired - Fee Related
-
2001
- 2001-07-10 ZA ZA200105652A patent/ZA200105652B/en unknown
-
2003
- 2003-06-16 US US10/463,841 patent/US20040037838A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6169171B1 (en) * | 1992-02-27 | 2001-01-02 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBSAG |
US6579524B1 (en) * | 1999-02-18 | 2003-06-17 | Rmf Dictagene S.A. | Malaria vaccine |
Also Published As
Publication number | Publication date |
---|---|
CA2359610A1 (en) | 2000-08-24 |
CZ20012957A3 (en) | 2001-12-12 |
BR0008285A (en) | 2001-11-27 |
CN1341150A (en) | 2002-03-20 |
HUP0200302A2 (en) | 2002-05-29 |
IL144750A0 (en) | 2002-06-30 |
US6579524B1 (en) | 2003-06-17 |
EP1151098A1 (en) | 2001-11-07 |
PL349861A1 (en) | 2002-09-23 |
MXPA01008176A (en) | 2002-08-30 |
WO2000049146A1 (en) | 2000-08-24 |
AU765801B2 (en) | 2003-10-02 |
NZ513549A (en) | 2003-03-28 |
ZA200105652B (en) | 2002-07-10 |
AU2805700A (en) | 2000-09-04 |
JP2002537310A (en) | 2002-11-05 |
CZ292475B6 (en) | 2003-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hoffman et al. | Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes | |
Benmohamed et al. | High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules | |
Arévalo-Herrera et al. | Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein | |
Céspedes et al. | Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein | |
Arévalo-Herrera et al. | Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants | |
Bermúdez et al. | Gauche+ side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine | |
US6669945B1 (en) | Universal T-cell epitopes for anti-malarial vaccines | |
US6579524B1 (en) | Malaria vaccine | |
Veiga et al. | Plasmodium vivax vaccine: What is the best way to go? | |
Roggero et al. | The synthetic, oxidized C‐terminal fragment of the Plasmodium. berghei circumsporozoite protein elicits a high protective response | |
Alves et al. | Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review | |
Caro-Aguilar et al. | Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria | |
Perlaza et al. | Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys | |
Perlaza et al. | Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice | |
Corradin et al. | Malaria vaccine development using synthetic peptides as a technical platform | |
US7198791B2 (en) | Compositions and methods for the generation of protective immune responses against malaria | |
Céspedes et al. | Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct | |
US7749519B2 (en) | Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax | |
Okitsu et al. | Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites | |
US20110262469A1 (en) | Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax | |
Pluschke et al. | Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation | |
EP4275700A2 (en) | Vaccine immunogens | |
Hockmeyer et al. | Recent efforts in the development of a sporozoite vaccine against human malaria | |
Trager et al. | Malaria vaccine | |
Nega et al. | Journal of Bacteriology & Parasitology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |